Open AccessPediatric Pleomorphic Xanthoastrocytoma: A National Database Inquiry on Current Treatment Approaches in the United States
Author(s) -
Scarpelli Daphne B.,
Yu Yun,
Tep Amanda C.,
Bergue Bailey,
Degnin Catherine,
Chen Yiyi,
McClelland Shearwood,
Jaboin Jerry J.
Publication year - 2021
Publication title -
cancer reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 5
ISSN - 2573-8348
DOI - 10.1002/cnr2.1415
Subject(s) - medicine , hazard ratio , confidence interval , chemotherapy , cohort , cancer , radiation therapy , oncology , database , surgery , computer science
Background Pleomorphic xanthoastrocytomas (PXAs) account for <1% of primary brain tumors, occurring predominantly in children and young adults. Surgical resection serves as the primary treatment for PXAs, while radiotherapy (RT) and chemotherapy protocols remain poorly defined. Aim This study aims to determine current care patterns utilized for pediatric patients (≤ 18 years) diagnosed with PXAs and their effect on overall survival. Methods The United States National Cancer Database (NCDB) was queried between 2004 and 2015 for pediatric patients (≤18 years) diagnosed with PXAs. Results From the 224 qualifying patients, most patients proceeded with surgery only (78.1%), while 11.6% of patients received both adjuvant RT and chemotherapy. In the 2010‐2015 cohort, patients with subtotal resection were associated with poorer prognosis than those with gross‐total resection (hazard ratio = 17.44, 95% confidence interval = 2.10‐144.90, p < .001). RT and chemotherapy recipients were similarly associated with poorer survival than those treated with surgery only, with p ‐values of <.001 and respective hazard ratios of 3.82 (95% confidence interval = 1.85‐7.90) and 6.68 (95% confidence interval = 3.21‐13.89). The key factors impacting the probability of RT delivery involved WHO grade ( p < .001) and chemotherapy administration ( p < .001). However, WHO grade alone did not significantly impact survival ( p ‐value = .088). Conclusion Maximally safe resection is the current treatment goal for patients with PXAs. RT and chemotherapy are poorly utilized but had a greater role in managing more aggressive cases of PXAs. Additional research focusing on the impact of adjuvant therapies on tumor progression is needed to better guide treatment decisions.